Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 28, 2016

Primary Completion Date

March 26, 2019

Study Completion Date

March 26, 2019

Conditions
HyperlipidemiaNAFLD
Interventions
DRUG

VK2809

DRUG

Placebo

Trial Locations (19)

10459

CHEAR Center, LLC, The Bronx

12533

Mid Hudson Medical, Hopewell Junction

27612

Wake Research Associcates, LLC., Raleigh

33173

Research Institute of South Florida, Miami

48503

Flint Clinical Research, PLLC, Flint

70526

Avant Research Associates, LLC, Crowley

77702

Avant Research, Beaumont

78229

Clinical Trials of Texas, INC, San Antonio

Radiant Research, Inc., San Antonio

84107

Wasatch Clinical Research, LLC, Salt Lake City

85224

Radiant Research, Inc., Chandler

91763

Catalina Research Institute, Montclair

91767

North America Research, Inc, Pomona

92780

Orange County Research Center, Tustin

92844

SC Clinical Research, Garden Grove

Unknown

ACTCA, Los Angeles

Research Institute of South Florida, Miami

HCI- MetroMedic Walk-in, New Bedford

02740

HCI- MetroMedic Walk-in, New Bedford

All Listed Sponsors
lead

Viking Therapeutics, Inc.

INDUSTRY

NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter